VivoSeq
Cardiovascular

Takotsubo Cardiomyopathy

5

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Takotsubo cardiomyopathy is an early-stage landscape with 5 programs across 4 companies. The most active players are Novartis, Teva, AstraZeneca. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

ApprovedTeva logo

Teva

1 program

PreclinicalAstraZeneca logo

AstraZeneca

1 program

PreclinicalP

Pensionsversicherungsanstalt

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy
Recruiting·UUniversity of Edinburgh·N/A·NCT07491718·100 enrolled
Effectiveness of a Resilience-based Rehabilitation Program in Patients With TakoTsubo Cardiomyopathy and After Acute Coronary Syndrome
Recruiting·PPensionsversicherungsanstalt·Preclinical·NCT06332859·130 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)